M Niranjan Reddy, MD
Interventional Cardiology · Wilmington, OHNPI 1780640102
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $71,325 of the $98,305 with a category attached, or 72.6%. 20 manufacturers reported payments, led by Abbott at 53.1% of the total. Reporting peaked in 2019 at $34,429 and has fallen 83.8% since, to $5,595 in 2025. Among interventional cardiology clinicians in OH with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 191 payments — averaging $514.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$52K
- Terumo Medical Corporation$28K
- Shockwave Medical, Inc$10K
- Medtronic$3K
- Penumbra, Inc.$2K
- Boston Scientific$964
- plus $3K from 14 others
Across 31 payments — averaging $1904.90 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Penumbra, Inc.$43K
- Abbott$10K
- AstraZeneca$5K
What the payments were for
- Consulting fees$71,32573%
- Speaking & faculty fees$6,6007%
- Travel & lodging$11,79112%
- Food & beverage$8,5899%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 54 | $52,203 |
| Terumo Medical Corporation | 36 | $28,181 |
| Shockwave Medical, Inc | 11 | $9,518 |
| Medtronic(2 entities) | 29 | $3,019 |
| Penumbra, Inc. | 8 | $1,582 |
| Boston Scientific | 17 | $964 |
| Abiomed | 10 | $870 |
| Angiodynamics, Inc. | 1 | $494 |
| Stryker | 2 | $287 |
| Veryan Medical Incorporated | 1 | $204 |
| Surmodics, Inc. | 1 | $151 |
| Endologix LLC | 2 | $136 |
| Impulse Dynamics (USA) Inc. | 1 | $135 |
| Inari Medical, Inc. | 1 | $130 |
| Cardiovascular Systems Inc. | 5 | $126 |
| AstraZeneca | 4 | $119 |
| Cagent Vascular Inc | 2 | $78 |
| Biotronik Inc. | 2 | $53 |
| Novartis | 2 | $28 |
| Sanofi-aventis U.S. LLC | 2 | $25 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Omnilink Elite vascular stent system$27,117
- Emboshield NAV6 system$11,517
- Xience V coronary stent system$11,269
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$9,281
- Indigo System$1,300
- ClosureFast$1,139
- TurboHawk$665
- SUPERA$600
- AlphaVac$494
- GLIDESHEATH SLENDER$434
- Impella$303
- METACROSS OTW$297
- OPTIMIZER$270
- FLOWTRIEVER CATHETER, S$262
- CT THROMBECTOMY SYSTEM KIT$262
- Xience Sierra Coronary Stent System$258
- BioMimics$204
- Diamondback Coronary$166
- Heartrail$160
- GlideWire$160
How this compares
$98,305 in reported general payments places this provider in the 90th percentile of 256 interventional cardiology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 507 | $513,516 |
| EntrestoSacubitril/Valsartan | 284 | $304,371 |
| BrilintaTicagrelor | 84 | $62,706 |
| XareltoRivaroxaban | 54 | $56,672 |
| Repatha SureclickEvolocumab | 45 | $55,534 |
| JardianceEmpagliflozin | 49 | $46,720 |
| MultaqDronedarone Hcl | 16 | $27,101 |
| FarxigaDapagliflozin Propanediol | 20 | $25,816 |
| Prasugrel Hcl | 53 | $11,694 |
| LivaloPitavastatin Calcium | 12 | $7,467 |
| Atorvastatin Calcium | 831 | $7,072 |
| Carvedilol | 873 | $5,821 |
| Amiodarone Hcl | 67 | $5,613 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 24 | $5,107 |
| ClopidogrelClopidogrel Bisulfate | 570 | $4,817 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $28 | $304,371284 claims |
| AstraZenecaBrilinta, Farxiga | $119 | $88,522104 claims |
| Sanofi-aventis U.S. LLCMultaq | $25 | $27,10116 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 256 interventional cardiology providers in Ohio.
Other interventional cardiology in Wilmington
- Gary AnselColumbus$3.3M
- John CheathamColumbus$1.4M
- Carlos Sanchez SotoColumbus$1.1M
- Steven YakubovColumbus$907K
- Timothy HenryCincinnati$605K
- Mitchell SilverColumbus$562K
- John PhillipsColumbus$410K
- John CorlCincinnati$390K
- Santiago GarciaCincinnati$360K
- Atish MathurMansfield$291K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.